Alto Neuroscience(US:ANRO) Globenewswire·2025-09-15 19:48Core Viewpoint - The Gross Law Firm has announced a class action lawsuit on behalf of shareholders of Alto Neuroscience, Inc. (NYSE: ANRO) who purchased shares during a specified class period, alleging that the company made materially false and misleading statements regarding its product pipeline and business prospects [1][4]. Group 1: Class Action Details - The class period for the lawsuit includes all persons and entities that purchased Alto common stock from February 2, 2024, to October 22, 2024 [3]. - Shareholders are encouraged to register for the class action by the deadline of September 19, 2025, to potentially be appointed as lead plaintiff [5]. Group 2: Allegations Against the Company - The complaint alleges that the product pipeline, specifically ALTO-100, was less effective in treating major depressive disorder than previously claimed, leading to overstated clinical and commercial prospects [4]. - As a result of these misleading statements, the company's business and financial outlook were also overstated, impacting the accuracy of public statements made by the company [4]. Group 3: Law Firm's Commitment - The Gross Law Firm aims to protect the rights of investors who have suffered losses due to deceit and illegal business practices, emphasizing the importance of responsible corporate behavior [6].